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months). One-, two-, three- and five LC rates were 92%, 
87%, 84% and 84%, respectively, with a median LC of 18 
months. At univariate analysis, the primary histology and 
previous local ablative therapies were significant (p<0.03 
and p< 0.006, respectively). At the time of analysis, 61 
patients (30%) are alive. Median OS was 21 months (18-24 
IC 95%) and the survival rates were 79%, 27% and 15% at 
1, 3 and 5 years after SBRT, respectively. At univariate 
analysis, sex, primitive disease, intra- and extra- hepatic 
progression were significant prognostic factors of 
survival. This analysis confirmed the absence of late 
toxicity > G3. Acute and late toxicity were detected in 
137 (68%) and 5 (2.4%) patients, respectively. 
Conclusion  
This study confirms the efficacy and safety of SBRT for 
unresectable liver metastases. Selection of cases with 
positive prognostic factors may improve survival and local 
control of these oligometastastic patients. A 
multidisciplinary evaluation is mandatory to define the 
best treatment for selected patient, in the optical of 
tailored therapeutic strategy. 
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Purpose or Objective  
Stereotactic body radiation therapy (SBRT) provides a 
high level of precision, enabling treatment of 
oligometastastatic (OM) cancer. The aim of this study was 
to describe dosimetry, and to evaluate the safety, short-
term efficacy, and quality of life in a phase II trial. 
Material and Methods  
A single institution, prospective, single-arm, phase II trial 
is currently ongoing for pts with OM cancer with up to 5 
sites of extracranial metastases, all planned to receive 
local ablative therapy, at least one index lesion being 
suitable for SBRT (5-fraction regimen). The study is 
designed to provide a unifying approach across disease 
site groups for pts presenting with potentially OM 
disease. All cases were peer reviewed to confirm 
eligibility and treatment plan. We evaluated dosimetry, 
toxicities (CTCAE G3+), QoL (EORTC QLQ-C30, EQ5D, and 
ESAS), PFS and OS for an interim analysis. 
Results  
Between Mar 7 2013 and Dec 31 2016, 197 pts were 
screened and 116 accrued, including 69 accrued before 
Dec 31 2015, with 12-month follow-up, who form the 
basis of this interim analysis. Median follow-up was 20 
months (1-48). Median age was 63.5 (36-86). Primary 
tumor sites were colon (19), lung (9), breast (5) and 
others (36). Fifty three patients had a single lesion. Index 
sites were in liver (19), lymph nodes (16), non-axial bone 
(10), adrenal (9), lung (8), axial bone (4) and other (3). 
Median prescribed dose was 40Gy (30-50Gy). For solitary 
non-spine SBRT plans, median PTV D80 (%) 102.6% (94.6-
113.5), D98 (%) 96.7% (73.5-102.8) and conformity index for 
95% isodose 1.2 (0.8-1.9). Dose-limiting luminal 
structures (defined as receiving ≥85% of dose limit) were 
duodenum (12%), stomach (17%), small bowel (10%), large 
bowel (9%) and esophagus (4%) receiving a median D0.5cc 
of 30 (28-31), 29Gy (26-30), 30Gy (29-30), 30Gy (29-32) 
and 30Gy (29-33) respectively. Liver was a dose-limiting 
organ in 6 (MLD 14.6Gy; range 13.2-15.3) and kidney in 3 
(Dmean 9Gy, 10Gy and 12Gy; limit Dmean<10Gy) pts. G3 
gastric bleeding occurred in 2pts at 5.4 and 9 months 
after treatment (stomach D0.5cc 29Gy and 30Gy). At 2 
years, freedom from local, distant and any progression 
was 68%, 21% and 19%, while OS was 80%. Fifty seven 
patients were eligible for 12-month QoL evaluation. In 10 
pts without disease progression, EORTC QLQ-C30 Global 
QoL domain showed significant improvement (+13; p = 
0.033), while in 47 pts who progressed, scores declined (-
7; p=0.08). 
Conclusion  
In pts presenting with OM disease, 59% were eligible for 
trial participation after screening. Luminal structures 
were dose limiting in 37% of pts precluding delivery of 
the maximal permissible levels. Pts were treated with 
highly conformal SBRT plans, which met the dosimetric 
goals for target coverage and normal tissue tolerances. 
SBRT as part of an ablative strategy is well tolerated, 
resulted in improved QoL in pts who were free from 
disease progression. Majority of pts experience early 
distant disease progression, although OS remains 
favourable. 
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Purpose or Objective  
To evaluate early clinical outcomes and cumulative organ 
at risk (OAR) doses in patients re-irradiated for 
oligometastatic disease in the pelvis using SABR.  
Material and Methods  
Patient records were reviewed for baseline and outcome 
data. Former and re-irradiation (reRT) dose distributions 
were reviewed to assess cumulative OAR doses. The 
intended reRT D95% was 30Gy in 5 fractions, but could be 
compromised to respect OAR tolerances. Response was 
assessed by imaging and/or PSA control in prostate 
cancer (PCa) patients. To evaluate cumulative doses, 
reRT PTVs were copied from the reRT plan to the rigidly 
registered former radiotherapy (RT) plan. To take 
account of potential anatomical and positional changes 
between RT courses (particularly for bowel), a 1cm 
expansion was created around the copied reRT PTV, and 
OARs within this volume were considered those at 
greatest risk from reRT. The maximum doses to 0.1cm3 
(Dmax0.1cc) delivered by the former plan to the OARs within 
this volume were recorded. These were added to the 
planned Dmax0.1cc for the corresponding OARs in the reRT 
plan to provide a 'worst case' estimate of cumulative 
dose. All doses were converted to 2Gy fraction equivalent 
(EQD2, α/β=3Gy) prior to summation. Repair was not 
considered. 
Results  
20 patients received SABR reRT for 30 oligometastatic 
pelvic lesions between 03/16 and 09/17. Table 1 shows 
baseline characteristics. Androgen deprivation was used 
concurrently with SABR in 12 PCa patients. Median time 
from former RT to reRT was 50.1 months (range 14.6-
93.8). Median D95% for the reRT PTV was 30.5Gy (range 
23-31.6) reflecting de-escalation in some cases due to 
OARs. Median follow up was 10.7 months. Of 11 imaged 
re-irradiated lesions, 3 were stable and 5 and 3 showed 
partial and complete responses, respectively. Local 
control, based on imaging or PSA control, was 100% at 1 
year. 13 of 16 PCa patients had a fall in PSA at 6-12 
weeks post-SABR. 6 of 10 imaged patients have developed 
imaged-defined out of field progression (median time to 
image-defined progression: 11.8 months) and 5 of 16 PCa 
patients have developed PSA progression (median time to 
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PSA progression: 11.3 months). All but one patient remain 
alive (1 year survival: 88.9%). No grade 3+ acute 
toxicities were observed and no grade 3+ late toxicities 
have been reported to date. Vessels were the OAR most 
often within the reRT PTV, but were not dose limiting. 
Small bowel, colon and sacral plexus were within the PTV 
in 7, 5 and 7 cases respectively and were potentially dose 
limiting. Cumulatively, allowing for potential positional 
change between RT courses, 'worst case' calculated doses 
to small bowel, colon and sacral plexus were up to 111, 
107 and 123Gy (EDQ2, α/β=3Gy), respectively (Table 2). 
 
 
 
Conclusion  
SABR reRT appears well tolerated and effective in 
controlling oligometastatic pelvic disease. Cumulative 
doses and positional changes in OARs between courses 
should be considered. SABR reRT requires further 
evaluation in prospective trials to guide future delivery. 
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Purpose or Objective  
Stereotactic body radiation therapy (SBRT) for painful 
spinal metastases has the potential to improve and 
extend pain relief, but prospective data on pain response 
are lacking. This prospective phase II trial addressed the 
question of overall (complete and partial) pain response 
after hypo-fractionated SBRT for painful, mechanically 
stable, previously un-irradiated spinal metastases?   
Material and Methods  
From 2012 to 2015, 54 patients were treated and 
analyzed in a prospective, multicenter, non-randomized, 
single arm phase 2 study (NCT01594892). Inclusion 
criteria were ≤2 distinct, non-contiguous, painful, 
mechanically stable, un-irradiated spinal metastases from 
a solid tumor, Karnofsky performance status ≥60. Patients 
with long (Mizumoto score ≤4) or intermediate (Mizumoto 
score 5-9) overall survival expectancy were treated with 
hypo-fractionated SBRT of 48.5 Gy in 10 fractions or 35 
Gy in 5 fractions, respectively. The primary outcome was 
overall (complete and partial) pain response measured 
with the International Consensus Guidelines at 3 months 
after SBRT; the secondary outcome was local control, 
survival, toxicity and quality-of-life measured with the 
Euro-quality-of-life Five Dimensions Questionnaire (EQ-
5D-5L). 
Results  
Of 54 patients (30 [56%] male; median [range] age 64 [25-
84] years; 60 lesions) 30 (56%) patients were treated with 
10-fraction SBRT and 24 (44%) with 5-fraction SBRT. Pain 
response at 3-months was evaluated in 42 patients (47 
lesions). Overall pain response was observed in 41 lesions 
(87%) and pain response remained stable for at least 12 
months. Mean (standard deviation) maximum pain scores 
on Visual Analogue Score significantly improved from 
baseline 6.1 (2.5)  to 2.0 (2.3) at 3 months post-
treatment (P<.001). EQ-5D-5L quality-of-life dimensions 
(self-reported mobility, usual activities and 
pain/depression) significantly improved from baseline to 
3 months post-treatment. After a median follow-up of 12 
months, the 12-month overall survival and local control 
rates were 61.4% (95% CI, 48-74.8%) and 85.9% (95% CI, 
76.7-95 %), respectively. Grade 3 toxicity was limited to 
acute pain in 1 patient (2%). No patient experienced 
radiation-induced myelopathy. Six (11%) and 8 (15%) 
patients developed progressive or new vertebral 
compression fractures (VCF), respectively, but 
stabilization (n=1) and decompression (n=1) surgery was 
only required in two patients.   
Conclusion  
SBRT for painful vertebral metastases achieved rapid, 
deep and long-term overall pain response, high local 
metastasis control and improved quality-of-life a nd may 
become a primary treatment in selected patients with 
longer survival expectancy.  
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Purpose or Objective  
Surgery is the standard of care for early stage lung 
cancer. Stereotactic ablative radiotherapy (SABR) is a low 
